Volume 5, Issue 3 (March 2013)

ISSN Print: 1949-4998   ISSN Online: 1949-5005

Google-based Impact Factor: 0.82  Citations  

Clopidogrel in ischemic heart disease: A critical appraisal

HTML  XML Download Download as PDF (Size: 43KB)  PP. 465-468  
DOI: 10.4236/health.2013.53063    4,565 Downloads   6,222 Views  


Aspirin and clopidogrel are the commonest dual antiplatelet agents being used in the secondary prevention of cardiovascular disease. In high risk patients with coronary heart disease, the use of aspirin was associated with a significant risk reduction of myocardial infarction, stroke and vascular death. The use of clopidogrel alone was slightly superior to aspirin, and associated with reduced risk of vascular death, ischemic stroke and myocardial infarction. Dual antiplatelet therapy has been well studied in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention (PCI). In patients with stable coronary heart disease or multiple risk factors the combination of clopidogrel plus aspirin was not significantly more effective than aspirin alone in reducing MI, stroke or death from cardiovascular causes.

Cite this paper

Al-Otaiby, M. and Al-Moghairi, A. (2013) Clopidogrel in ischemic heart disease: A critical appraisal. Health, 5, 465-468. doi: 10.4236/health.2013.53063.

Cited by

No relevant information.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.